Elliott Crigger, PhD and Christopher Khoury, MSc, MBA
In 2018, the AMA provided a broad framework for evolving AI in health care designed to help realize the benefits it promises for patients and clinicians.
AMA J Ethics. 2019;21(2):E188-191. doi:
10.1001/amajethics.2019.188.
Haley Moulton, Benjamin Moulton, JD, MPH, Tim Lahey, MD, MMSc, and Glyn Elwyn, MD, PhD, MSc
Shared decision making in research informed consent conversations is complex due to diverse and potentially divergent interests of investigators and patient-subjects.
AMA J Ethics. 2020;22(5):E365-371. doi:
10.1001/amajethics.2020.365.
AI might improve patient-clinician relationships, but various underlying assumptions will need to be addressed to bring these potential benefits to fruition.
AMA J Ethics. 2020;22(5):E395-400. doi:
10.1001/amajethics.2020.395.
William F. Parker, MD, MS and Marshall H. Chin, MD, MPH
Given organ scarcity, transplantation programs state that patient promises of compliance cannot be taken at face value, excluding candidates who are deemed untrustworthy.
AMA J Ethics. 2020;22(5):E408-415. doi:
10.1001/amajethics.2020.408.
Drs Katrina Bramstedt and Ana Iltis discuss the development of QoL assessment tools to help patient-subjects considering reconstructive transplantation.
As larger organizations become more influential in the health care sector, the Code can help physicians navigate those organizations’ influence on their practices.
AMA J Ethics. 2020;22(3):E217-220. doi:
10.1001/amajethics.2020.217.
Upcoding and misrepresenting clinical information constitute fraud, cost a lot, and can result in patient harm and unnecessary procedures and prescriptions.
AMA J Ethics. 2020;22(3):E221-231. doi:
10.1001/amajethics.2020.221.
Corporatization in health care has complicated clinicians’ and organizations’ efforts to balance interests of individual patients against an organization’s bottom line.
AMA J Ethics. 2020;22(3):E187-192. doi:
10.1001/amajethics.2020.187.